HER2 status in Barrett's esophagus & esophageal cancer: A meta analysis

Journal of Gastrointestinal Oncology

Volumn 5, Issue 1, 2014, Pages 25-35

  Gowryshankar, Ashwini ^a   Nagaraja, Vinayak ^a   Eslick, Guy D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Barrett's esophagus (BE); Esophageal cancer (EC); Human epidermal growth factor receptor 2 (HER2); Meta analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; ARTICLE; ASIA; BARRETT ESOPHAGUS; CANCER PATIENT; CANCER SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PREVALENCE; PROTEIN ANALYSIS; QUANTITATIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

EID: 84995785839     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2013.039     Document Type: Article

References (60)

1. Lepage C, Rachet B, Jooste V, et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 2008;103:2694-9.
2. Bremholm L, Funch-Jensen P, Eriksen J, et al. Barrett's esophagus. Diagnosis, follow-up and treatment. Dan Med J 2012;59:C4499.
3. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012;23:3155-62.
4. Wang S, Zheng G, Chen L, et al. Effect of HER-2/neu over-expression on prognosis in gastric cancer: a metaanalysis. Asian Pac J Cancer Prev 2011;12:1417-23.
5. Picardo SL, Maher SG, O'Sullivan JN, et al. Barrett's to oesophageal cancer sequence: a model of inflammatorydriven upper gastrointestinal cancer. Dig Surg 2012;29:251-60.
6. Mahzouni P, Movahedipour M. An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade. Pathol Res Pract 2012;208:221-4.
7. Agarwal A, Polineni R, Hussein Z, et al. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol 2012;5:382-96.
8. Yu GZ, Chen Y, Wang JJ, et al. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009;135:1331-9.
9. Liang Z, Zeng X, Gao J, et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 2008;8:363.
10. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti- HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
11. Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 2012;23:765-76.
12. Guiu S, Arnould L, Bonnetain F, et al. Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study. Breast 2013;22:301-8.
13. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
15. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
16. Egger M, Smith GD, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315:629-34.
17. Orwin RG. A fail-safe N for effect size in meta-analysis. Journal of Educational Statistics 1983;8:157-9.
18. Rossi E, Villanacci V, Bassotti G, et al. TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology 2010;57:81-9.
19. Rauser S, Weis R, Braselmann H, et al. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 2007;13:5115-23.
20. Brien TP, Odze RD, Sheehan CE, et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000;31:35-9.
21. Walch A, Specht K, Bink K, et al. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Lab Invest 2001;81:791-801.
22. Geddert H, Zeriouh M, Wolter M, et al. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol 2002;118:60-6.
23. Fléjou JF, Paraf F, Muzeau F, et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 1994;47:23-6.
24. Hardwick RH, Shepherd NA, Moorghen M, et al. c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. J Clin Pathol 1995;48:129-32.
25. Nakamura T, Nekarda H, Hoelscher AH, et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994;73:1785-94.
26. Kim R, Clarke MR, Melhem MF, et al. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 1997;42:2453-62.
27. Walch A, Bink K, Hutzler P, et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000;31:1332-4.
28. Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012;18:546-54.
29. Thompson SK, Sullivan TR, Davies R, et al. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 2011;18:2010-7.
30. Hu Y, Bandla S, Godfrey TE, et al. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 2011;24:899-907.
31. Reichelt U, Duesedau P, Tsourlakis M, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120-9.
32. Hardwick RH, Barham CP, Ozua P, et al. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol 1997;23:30-5.
33. Duhaylongsod FG, Gottfried MR, Iglehart JD, et al. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 1995;221:677-83.
34. Sauter ER, Keller SM, Erner S, et al. HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus. Cancer Lett 1993;75:41-4.
35. Langer R, Rauser S, Feith M, et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol 2011;24:908-16.
36. Friess H, Fukuda A, Tang WH, et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 1999;23:1010-8.
37. Mimura K, Kono K, Hanawa M, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005;92:1253-60.
38. Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008;13:441-53.
39. Polkowski W, van Sandick JW, Offerhaus GJ, et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999;6:290-7.
40. Sato-Kuwabara Y, Neves JI, Fregnani JH, et al. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer 2009;9:6.
41. Yamamoto Y, Yamai H, Seike J, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Ann Surg Oncol 2012;19:757-65.
42. Birner P, Jesch B, Friedrich J, et al. Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression. Ann Surg Oncol 2011;18:3330-7.
43. Wei Q, Chen L, Sheng L, et al. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 2007;31:493-9.
44. Sano A, Kato H, Sakurai S, et al. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol 2009;16:506-14.
45. Zhan N, Dong WG, Tang YF, et al. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol 2012;29:933-40.
46. Bizari L, Borim AA, Leite KR, et al. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet 2006;165:41-50.
47. Schoppmann SF, Jesch B, Zacherl J, et al. HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases. Br J Surg 2011;98:1408-13.
48. Engelstaedter V, Schiffers J, Kahlert S, et al. Her-2/neu and topoisomerase IIalpha in advanced breast cancer: a comprehensive FISH analysis of 245 cases. Diagn Mol Pathol 2012;21:77-83.
49. Ryu DW, Lee CH. Impact of Serum HER2 Levels on Survival and Its Correlation with Clinicopathological Parameters in Women with Breast Cancer. J Breast Cancer 2012;15:71-8.
50. Villanacci V, Rossi E, Grisanti S, et al. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. Minerva Gastroenterol Dietol 2008;54:347-53.
51. Zhang H, Chen Z, Cheng J, et al. The high incidence of esophageal cancer in parts of China may result primarily from genetic rather than environmental factors. Dis Esophagus 2010;23:392-7.
52. Zheng S, Vuitton L, Sheyhidin I, et al. Northwestern China: a place to learn more on oesophageal cancer. Part one: behavioural and environmental risk factors. Eur J Gastroenterol Hepatol 2010;22:917-25.
53. Zhang N, Yu C, Wen D, et al. Association of nitrogen compounds in drinking water with incidence of esophageal squamous cell carcinoma in Shexian, China. Tohoku J Exp Med 2012;226:11-7.
54. He Z, Zhao Y, Guo C, et al. Prevalence and risk factors for esophageal squamous cell cancer and precursor lesions in Anyang, China: a population-based endoscopic survey. Br J Cancer 2010;103:1085-8.
55. Dreilich M, Wanders A, Brattstrom D, et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006;19:224-31.
56. Akamatsu M, Matsumoto T, Oka K, et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003;57:1323-7.
57. Uno M, Otsuki T, Kurebayashi J, et al. Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma. Int J Cancer 2001;94:474-9.
58. Ahmed SS, Iqbal J, Thike AA, et al. HER2/neu revisited: quality and interpretive issues. J Clin Pathol 2011;64:120-4.
59. Barrett C, Magee H, O'Toole D, et al. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? J Clin Pathol 2007;60:690-3.
60. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.